Thomas Schinecker

Thomas Schinecker

politician unknown

Thomas Schinecker is the CEO of Roche, a leading global healthcare company. He is also a member of the board of the Lucerne Festival, where he contributes to the strategic direction of this renowned cultural institution.

Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
6,985
Power
565$
Sentiment
7.00
Countries Mentioned
Country Mentions Sentiment Dominance + Persistence x Population = Reach x GDP (millions) = Power
Switzerland 1 7.00 0.08% +0% 8,654,622 6,985 $700,000 565$
Totals 1 8,654,622 6,985 $700,000 565$
Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

Switzerland Switzerland: Thomas Schinecker, the CEO of Roche, defends against accusations of sluggishness in business development. 7

Neue Zürcher Zeitung: Der Roche-Chef Thomas Schinecker wehrt sich gegen Vorwürfe der Trägheit

Switzerland Switzerland: Thomas Schinecker is the CEO of Roche and has been pivotal in the company's research and development efforts since his appointment in 2023. 7

Neue Zürcher Zeitung: Roche macht deutlich mehr Gewinn

Switzerland Switzerland: Thomas Schinecker is the CEO of Roche and commented on the potential impact of US negotiations on drug prices. 5

Neue Zürcher Zeitung: Droht eine Verknüpfung mit den Medikamentenpreisen?

Switzerland Switzerland: Thomas Schinecker, the CEO of Roche, has made demands regarding drug pricing in Switzerland. 6

Neue Zürcher Zeitung: «Standortwettbewerb hat neue Dimension erreicht»

Switzerland Switzerland: Thomas Schinecker is the CEO of Roche who commented on the implications of the agreement with the US government. 6

Neue Zürcher Zeitung: Willkommener Weckruf für die Schweiz

Switzerland Switzerland: Thomas Schinecker, the CEO of Roche, emphasized the geographical flexibility of global companies compared to Switzerland. 6

Neue Zürcher Zeitung: Schlaraffenland in Gefahr: Droht Basel der Pharma-Abschwung?

Switzerland Switzerland: Thomas Schinecker mentioned that prices could be halved by eliminating intermediaries. 5

Neue Zürcher Zeitung: Optionen für Roche und Novartis nach Trumps Zolldrohungen